Premium
Heterogeneous phenotype of human glioblastoma: In vitro study
Author(s) -
Denysenko Tetyana,
Gennero Luisa,
Juenemann Carola,
Morra Isabella,
Masperi Paolo,
Ceroni Vincenzo,
Pragliola Antonella,
Ponzetto Antonio,
Melcarne Antonio
Publication year - 2014
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.2988
Subject(s) - neurosphere , cancer stem cell , mesenchymal stem cell , biology , stem cell , cancer research , population , cell culture , stem cell marker , phenotype , cell , in vitro , cell growth , cellular differentiation , side population , microbiology and biotechnology , adult stem cell , endothelial stem cell , medicine , genetics , gene , environmental health
Glioblastomas (GBMs) are the most lethal primary brain tumours. Increasing evidence shows that brain tumours contain the population of stem cells, so‐called cancer stem cells (CSCs). Stem cell marker CD133 was reported to identify CSC population in GBM. Further studies have indicated that CD133 negative cells exhibiting similar properties and are able to initiate the tumour, self‐renew and undergo multilineage differentiation. GBM is a highly heterogeneous tumour and may contain different stem cell populations with different functional properties. We characterized five GBM cell lines, established from surgical samples, according to the marker expression, proliferation and differentiation potential. CD133 positive cell lines showed increased proliferation rate in neurosphere condition and marked differentiation potential towards neuronal lineages. Whereas two cell lines low‐expressing CD133 marker showed mesenchymal properties in vitro , that is high proliferation rate in serum condition and differentiation in mesenchymal cell types. Further, we compared therapy resistance capacity of GBM cell lines treated with hydroxyurea. Our results suggest that CSC concept is more complex than it was believed before, and CD133 could not define entire stem cell population within GBM. At least two different subtypes of GBM CSCs exist, which may have different biological characteristics and imply different therapeutic strategies. Copyright © 2013 John Wiley & Sons, Ltd.